We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Gut Bacteria Byproduct Predicts Heart Attack

By LabMedica International staff writers
Posted on 15 May 2013
A microbial byproduct of intestinal bacteria contributes to heart disease and serves as an accurate screening tool for predicting future risks of heart attack.

A relationship has been discovered between the biochemical by product trimethylamine N-oxide (TMAO) levels and future cardiac events like heart attack, stroke, and death, even in those with no prior evidence of cardiac disease risk. More...


Scientists at the Cleveland Clinic (Cleveland, OH, USA) examined the relationship between fasting plasma levels of TMAO and the incidence of major adverse cardiovascular events, including death, myocardial infarction, or stroke during three years of follow-up in 4,007 patients undergoing elective coronary angiography.

The investigators used a stable-isotope-dilution assay and high-performance liquid chromatography with online electrospray ionization tandem mass spectrometry on the QTRAP 5500 mass spectrometer (AB SCIEX; Framingham, MA, USA) to quantify the TMAO, trimethylamine, choline, betaine, and their d9-isotopologues.

The scientists found that higher TMAO blood levels were associated with higher future risks of death and nonfatal heart attack or stroke over the ensuing three-year period, independent of other risk factors and blood test results. Participants who had major adverse cardiovascular events also had higher baseline levels of TMAO with a median of 5.0 μM, as compared with those who did not have cardiovascular events, whose median was 3.5 μM, which was statistically significant.


The authors concluded that intestinal microbes participate in phosphatidylcholine metabolism to form circulating and urinary TMAO. They established a correlation between high plasma levels of TMAO and an increased risk of incident major adverse cardiovascular events that is independent of traditional risk factors, even in low-risk cohorts. Stanley L. Hazen, MD, PhD, a lead author of the study, said, “These studies show that measuring blood levels of TMAO could serve as a powerful tool for predicting future cardiovascular risk, even for those without known risk factors. More studies are needed to confirm that TMAO testing, like cholesterol, triglyceride or glucose levels might help guide physicians in providing individualized nutritional recommendations for preventing cardiovascular disease.” The study was published on April 25, 2013, in the New England Medical Journal.

Related Links:
Cleveland Clinic
AB SCIEX



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.